<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Twenty patients with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (SAA) were treated with low doses (1-5 mg/kg/day) of a high-potency antithymocyte globulin (ATG) produced in Mexico, shown to have at least a 10-fold potency as compared with other globulins of commercial sources </plain></SENT>
<SENT sid="1" pm="."><plain>Patients received ATG within a 10-day period, every other day (5 doses) at a dose of 1 mg/kg/day (4 courses), 2 mg/kg/day (12 courses) or 5 mg/kg/day (8 courses) </plain></SENT>
<SENT sid="2" pm="."><plain>Four patients received 2 consecutive courses of different doses of ATG </plain></SENT>
<SENT sid="3" pm="."><plain>A response rate of 42% was recorded in the group, assessed by means of increases in reticulocytes, granulocytes or platelets </plain></SENT>
<SENT sid="4" pm="."><plain>One patient showed a complete remission </plain></SENT>
<SENT sid="5" pm="."><plain>The 570-day survival of the group was 51% </plain></SENT>
<SENT sid="6" pm="."><plain>It is concluded that the domestically produced ATG is useful in the treatment of some patients with SAA in Mexico </plain></SENT>
</text></document>